Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 6/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | BCR | P11274 | 1/20 | 0.51 |
| ▸ | IDH2 | P48735 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387447 | 0.89 | THRB (0.80) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL13778007 | 0.82 | THRB (1.00) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL374140 | 0.82 | THRB (0.70) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL374332 | 0.82 | THRB (0.74) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL30141460 | 0.82 | THRB (0.65) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL4239042 | 0.81 | THRB (0.68) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL15533814 | 0.79 | ABL1 (0.59) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL4239038 | 0.79 | AURKA (0.70) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL8798662 | 0.78 | AURKA (0.63) | THRBEGFRERBB4AURKAKDM4E | |
| SCHEMBL856156 | 0.77 | MEN1 (0.56) | EGFRKDM4ETSHRTNNI3KMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | THRB 2698/4885EGFR 3068/4885ERBB4 3400/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | THRB 3537/4885EGFR 1846/4885ERBB4 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.